Results 221 to 230 of about 3,844,628 (256)
Some of the next articles are maybe not open access.
IL28B in the Era of Direct-acting Antivirals for Hepatitis C
Journal of Clinical Gastroenterology, 2013The IL28B genotype is the strongest baseline predictor of hepatitis C treatment response with peginterferon-α and ribavirin. In 2011, 2 protease inhibitors were approved for genotype 1 infection in combination with peginterferon-α and ribavirin, and boceprevir and telaprevir attenuate the association between the IL28B genotype and treatment response ...
openaire +2 more sources
Direct acting antiviral therapy after liver transplantation
Current Opinion in Gastroenterology, 2016Historically, postliver transplant patients with chronic hepatitis C have had worse outcomes than nonhepatitis C-related causes because of accelerated fibrosis posttransplantation and the lack of effective well tolerated therapies for hepatitis C, and posttransplant hepatitis C patients have been considered a special population.
openaire +2 more sources
Direct-acting antiviral treatment for HCV
The Lancet Infectious Diseases, 2016Stelliana, Goutzamanis +4 more
openaire +2 more sources
Direct-Acting Antiviral Agents
Clinics in Liver Disease, 2015Tatyana Kushner, Vandana Khungar
openaire +1 more source
Direct-acting antiviral agents for the treatment of HCV
Antiviral Therapy, 2012Alexander J, Thompson +1 more
openaire +2 more sources
Direct‐acting antivirals and recurrence of hepatocellular carcinoma
Liver Transplantation, 2017Jorge A, Marrero, Amit G, Singal
openaire +2 more sources
Direct-acting antiviral treatment for hepatitis C
The Lancet, 2019Jacinta A, Holmes +2 more
openaire +2 more sources